Guidant, Boston Scientific Stocks Weather DES Issues
This article was originally published in The Gray Sheet
Executive Summary
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May